Articles
Comparing histamine intolerance and non-clonal mast cell activation syndrome.
Cimolai N. Comparing histamine intolerance and non-clonal mast cell activation syndrome. Intest Res. 2020;18(1):134-135. doi:10.5217/ir.2019.00087
The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS)
Kohn A, Chang C. The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273-297. doi:10.1007/s12016-019-08755-8
Effect of Dietary Fiber and Metabolites on Mast Cell Activation and Mast Cell-Associated Diseases
Folkerts J, Stadhouders R, Redegeld FA, et al. Effect of Dietary Fiber and Metabolites on Mast Cell Activation and Mast Cell-Associated Diseases. Front Immunol. 2018;9:1067. Published 2018 May 29. doi:10.3389/fimmu.2018.01067
Cellular Energetics of Mast Cell Development and Activation
Mendoza RP, Fudge DH, Brown JM. Cellular Energetics of Mast Cell Development and Activation. Cells. 2021;10(3):524. Published 2021 Mar 2. doi:10.3390/cells10030524
Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing
Altmüller J, Haenisch B, Kawalia A, et al. Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing. Immunogenetics. 2017;69(6):359-369. doi:10.1007/s00251-017-0981-y
Successful treatment of mast cell activation syndrome with sunitinib
Afrin LB, Cichocki FM, Patel K, Molderings GJ. Successful treatment of mast cell activation syndrome with sunitinib. Eur J Haematol. 2015;95(6):595-597. doi:10.1111/ejh.12606
Successful targeted treatment of mast cell activation syndrome with tofacitinib
Afrin LB, Fox RW, Zito SL, Choe L, Glover SC. Successful targeted treatment of mast cell activation syndrome with tofacitinib. Eur J Haematol. 2017;99(2):190-193. doi:10.1111/ejh.12893
Generalized Pruritus Relieved by NSAIDs in the Setting of Mast Cell Activation Syndrome
Kesterson K, Nahmias Z, Brestoff JR, Bodet ND, Kau A, Kim BS. Generalized pruritus relieved by NSAIDs in the setting of mast cell activation syndrome. J Allergy Clin Immunol Pract. 2018;6(6):2130-2131. doi:10.1016/j.jaip.2018.03.002
Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases
Espinosa E, Valitutti S, Laroche M, et al. Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. Clin Immunol. 2018;194:75-79. doi:10.1016/j.clim.2018.07.004
Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab
Berry R, Hollingsworth P, Lucas M. Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab. Clin Transl Immunology. 2019;8(10):e01075. Published 2019 Sep 30. doi:10.1002/cti2.1075
Utility of hydroxyurea in mast cell activation syndrome
Afrin LB. Utility of hydroxyurea in mast cell activation syndrome. Exp Hematol Oncol. 2013;2(1):28. Published 2013 Oct 9. doi:10.1186/2162-3619-2-28
A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders
Jan Romantowski, Aleksandra Górska, Marek Niedoszytko, Theo Gülen et al (2021). This article explores the diagnosis and management of patients suffering from mastocytosis and associated MCAS. Specifically, it focuses on diagnostic tests such as allergen microarrays and basophil activation tests, as well as targeted therapies.
Clinical Approach to Mast Cell Activation Syndromes: A Practical Overview
Matito A, Escribese MM, Longo N, et al. Clinical Approach to Mast Cell Activation Syndromes: A Practical Overview [published online ahead of print, 2021 Feb 4]. J Investig Allergol Clin Immunol. 2021;0. doi:10.18176/jiaci.0675
New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019
Michel Arock, Karl Sotlar, Jason Gotlib, et al (2021). This article summarises advances in the research of mast cell activation syndromes, as presented at the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. It discusses topics such as new therapeutic concepts in mastocytosis, updated prognostic tools, and recent findings from studies on mast cell activation (MCA) and mast cell activation syndromes (MCAS).
Mast Cell Activation: When the Whole Is Greater than the Sum of Its Parts
Dilawar Khokhar, Cem Akin (2020). This article discusses the complexity of diagnosing mast cell activation syndrome (MCAS) due to nonspecific symptoms, heterogeneity of presentation, and limitations to diagnostic criteria. It emphasizes the need for a systematic, evidence-based diagnostic approach to avoid misdiagnosis, unnecessary testing, and ineffective treatment.
Mast cell activation syndromes - evaluation of current diagnostic criteria and laboratory tools in clinical practice (Review)
Leru PM, Anton VF, Ureche C, Zurac S, Bratu O, Neagoe CD. Mast cell activation syndromes - evaluation of current diagnostic criteria and laboratory tools in clinical practice (Review). Exp Ther Med. 2020;20(3):2348-2351. doi:10.3892/etm.2020.8947
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine
Valent P, Akin C, Nedoszytko B, et al. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci. 2020;21(23):9030. Published 2020 Nov 27. doi:10.3390/ijms21239030
How to diagnose mast cell activation syndrome: practical considerations
Romantowski J, Górska A, Lange M, Nedoszytko B, Gruchała-Niedoszytko M, Niedoszytko M. How to diagnose mast cell activation syndrome: practical considerations. Pol Arch Intern Med. 2020;130(4):317-323. doi:10.20452/pamw.15212
Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes
Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther. 2013;35(5):548-562. doi:10.1016/j.clinthera.2013.04.001
Non-Clonal Mast Cell Activation: A Growing Body of Evidence
Hamilton MJ. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence. Immunol Allergy Clin North Am. 2018;38(3):469-481. doi:10.1016/j.iac.2018.04.002
Become a friend
Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives.
Donate
Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference to those affected by MCAS.
